Maersk has entered into an agreement of partnership with manufacturer COVAXX for the distribution of its COVID-19 vaccine — which is currently in phase 1 clinical trials.
The agreement lays out a framework for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world, once approved by regulatory authorities.
COVAXX is currently conducting Phase 1 clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval. The company has advanced pre-commitments for over 100 million doses of UB-612 around the globe.
The mission of COVAXX is to defeat COVID-19 and ultimately democratise health worldwide. Maersk will help fulfill this mission by overseeing all logistics activities to ensure efficient transportation to developing countries. The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain.
“Efficient and safe delivery of COVID-19 vaccines around the world is the most urgent logistics challenge we face today. A P Møller – Mærsk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available,” said Rob Townley, Head of Special Project Logistics at Maersk. “Our specialised logistics expertise and the global infrastructure of Maersk make this a perfect match.”
“Our team, which now proudly includes Maersk, is committed to addressing the needs of countries where the greatest unmet needs exist today,” said Mei Mei Hu, Co-Chief Executive Officer of COVAXX. “To do what is in the best interests of society at this time of the global health crisis, we are aligning with the strongest leaders in their respective industries to meet the large-scale demand and compliance requirements that we expect. It is not enough to focus on vaccine development and approvals. We must work in parallel to establish the infrastructure and partners with the strongest capabilities, like Maersk, to safely deliver our vaccine around the world.”
Overall, COVAXX aims to manufacture around 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021. The design of the vaccine components will enable the use of existing cold chain storage and distribution channels, as the COVAXX vaccine doesn’t require additional infrastructure like -80⁰C freezers or liquid nitrogen tanks to store materials at extreme temperatures.
“The COVAXX vaccine is unique in that it can be stored in the fridge you have at home, moved in the same trucks that deliver groceries and administered anywhere you can get a flu shot,” stated Lou Reese Co-Chief Executive Officer of COVAXX.